Vidac Pharma Holdings plc has released promising results for VDA-1275 in mouse cancer and human cellular organoid models of solid tumors, with VDA-1275 showing efficacy as a monotherapy and synergistic effects in combination with sorafenib and cisplatin.

Lantern Pharma Inc. has generated a new class of highly specific and highly potent antibody-drug conjugates (ADCs) with a cryptophycin drug-payload, in collaboration with Bielefeld University.

Redx Pharma plc has closed its biggest transaction to date, selling a preclinical KRAS inhibitor program to Jazz Pharmaceuticals plc in a potential $880 million deal. Of that, $10 million will be paid up front, with the balance to come in development and commercialization milestones. For any product that makes it to market, Redx will in addition receive tiered mid-single digit percentage royalties.

Accent Therapeutics Inc. has completed a $75 million series C financing to support progression of its lead programs through early clinical development.

Cytomx Therapeutics Inc. has received clearances from the FDA for IND applications for two conditionally activated Probody therapeutics.

Dxcover Ltd. initiated three pivotal trials to measure the efficacy of its liquid biopsy platform for early detection of brain, colorectal and lung cancers. The company hopes the trials will provide the evidence needed to gain regulatory approval and begin commercial operations of its diagnostic technology in Europe and the U.S.

PDC*line Pharma SA has announced the selection of the PDC*neo+ project for funding by the Walloon region of Belgium and Biowin, the health cluster for Wallonia.

PDC*line Pharma SA has received €4.7 million (US$5.1 million) in public funding as part of a €12.5 million project to apply its allogeneic leukemia-derived dendritic cell line in the development of personalized vaccines for treating colorectal cancer.